Compare XPEL & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPEL | VERA |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 3.4B |
| IPO Year | N/A | 2021 |
| Metric | XPEL | VERA |
|---|---|---|
| Price | $51.48 | $43.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $76.60 |
| AVG Volume (30 Days) | 197.4K | ★ 1.1M |
| Earning Date | 02-25-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $461,460,000.00 | N/A |
| Revenue This Year | $16.20 | N/A |
| Revenue Next Year | $11.28 | N/A |
| P/E Ratio | $30.75 | ★ N/A |
| Revenue Growth | ★ 10.29 | N/A |
| 52 Week Low | $24.25 | $18.53 |
| 52 Week High | $55.84 | $56.05 |
| Indicator | XPEL | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 48.94 | 42.76 |
| Support Level | $51.32 | $40.87 |
| Resistance Level | $54.32 | $45.51 |
| Average True Range (ATR) | 1.74 | 2.18 |
| MACD | -0.37 | -0.67 |
| Stochastic Oscillator | 25.34 | 22.10 |
XPEL Inc is a supplier of protective films, coatings, and related services to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from the sale of automotive products and related services while the remainder of its revenue is derived from non-automotive products including architectural window film and marine and flat surface protection films. The majority of revenue is derived from the United States.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.